Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Interactive Features

Quiz
Quiz: Treatment-Related Adverse Events in Patients with NSCLC Treated With Tiragolumab Plus Atezolizumab
09/08/2022
What did the phase 2 CITYSCAPE trial find to be the most common treatment-related adverse event in patients with non-small cell lung cancer treated with a combination of tiragolumab and atezolizumab?
What did the phase 2 CITYSCAPE trial find to be the most common treatment-related adverse event in patients with non-small cell lung cancer treated with a combination of tiragolumab and atezolizumab?
What did the phase 2 CITYSCAPE...
09/08/2022
Oncology
Quiz
Quiz: Agradasib-Related Adverse Events in Patients With KRAS-Mutated NSCLC
09/08/2022
According a phase 2 study, what percentage of patients with KRASG12C-mutated NSCLC experienced treatment-related adverse events when treated with adagrasib?
According a phase 2 study, what percentage of patients with KRASG12C-mutated NSCLC experienced treatment-related adverse events when treated with adagrasib?
According a phase 2 study, what...
09/08/2022
Oncology
elderly screening patient
Quiz
Novel MS-VMAT Technique for Whole Lung Irradiation
03/15/2022
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting,...
03/15/2022
Oncology

Advertisement

Test Your Knowledge
Quiz: Is Lurbinectedin Beneficial for Patients with Pretreated SCLC and Mesothelioma?
12/09/2021
True or false: According to real-world data, lurbinectedin did not demonstrate clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma.
True or false: According to real-world data, lurbinectedin did not demonstrate clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma.
True or false: According to...
12/09/2021
Oncology
Quiz
Quiz: Dose Escalation in Esophageal Cancer
08/15/2021
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to...
08/15/2021
Oncology
Test Your Knowledge
Quiz: Pembrolizumab Plus CRT for Locally Advanced NSCLC
08/09/2021
True or false: Pembrolizumab in combination with concurrent chemoradiation therapy offered promising clinical activity in patients with locally advanced non-small cell lung cancer.
True or false: Pembrolizumab in combination with concurrent chemoradiation therapy offered promising clinical activity in patients with locally advanced non-small cell lung cancer.
True or false: Pembrolizumab in...
08/09/2021
Oncology

Advertisement

Test Your Knowledge
Quiz: Is Pralsetinib Beneficial for RET+ NSCLC?
08/06/2021
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib...
08/06/2021
Oncology
Test Your Knowledge
Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?
08/03/2021
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of...
08/03/2021
Oncology
Test Your Knowledge
Quiz: Which treatment benefits patients with KRAS p.G12C-mutated non-small cell lung cancer?
07/06/2021
Which treatment showed efficacy and manageable safety in patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer?
Which treatment showed efficacy and manageable safety in patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer?
Which treatment showed efficacy...
07/06/2021
Oncology

Advertisement

Test Your Knowledge
Quiz: Which Treatment Received FDA Approval for ALK+ NSCLC?
03/23/2021
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
Which of the following...
03/23/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use